cerebrospinal News
-
Brain emergency averted at the push of a button
A Boston neurosurgeon recently avoided doing emergency brain surgery on a young patient just by pressing on a new device. The Alivio ReFlow ventricular system was embedded beneath the scalp of the unidentified hydrocephalus patient. Comprised of a subcutaneous “flusher” component and a ventricular catheter, the device has a “relief membrane” backup feature at the ...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of ...
-
Anuncia Releases User Guide Video for the ReFlow Mini Flusher
Step 1: Locate Locate the ReFlow Mini Flusher dome under the skin by touch. First, find the incision. Starting at the incision, trace toward the back of the head to find the flusher dome by touch. The ReFlow Mini Flusher dome will be located closest to the ventricular catheter and incision site. The valve is located after the flusher and should not be used for flushing. Step 2: Press Down ...
-
FONAR Subsidiary, HMCA, Expands with Acquisition in Yonkers, New York
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning, announced today that it has acquired a Stand-Up MRI facility in Yonkers, New York, from where its diagnostic imaging management subsidiary, Health Management Company of America (HMCA) will provide non-medical management services for Comprehensive MRI of New York, P.C. Tim Damadian, president and CEO of FONAR Corporation, said, ...
-
EnClear Therapies Announces $10M Series A Financing
Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors -- Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight Capital, and Dolby Ventures EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, ...
-
First Patient Treated in Polyganics’ ENCASE II Trial for Innovative Dura Sealant Patch, LIQOSEAL
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patient in its ENCASE II clinical trial for LIQOSEAL. LIQOSEAL is an easy-to-use, synthetic dura sealant patch indicated for use as an adjunct to standard methods of cranial dural repair, to provide watertight closure of the dura mater and ...
-
Alcyone Lifesciences Completes Spin-Off of Hydrocephalus Business, Anuncia
Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company focused on better treatment of Hydrocephalus and cerebrospinal fluid dysfunctions. The separation and ...
-
MDA Venture Philanthropy Grant to Support Development of ALS Biomarkers
The Muscular Dystrophy Association is pleased to announce the award of an MDA Venture Philanthropy (MVP) grant totaling $233,200 to Scottsdale, Ariz.-based Iron Horse Diagnostics to support development of a prognostic test for ALS (amyotrophic lateral sclerosis). Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. MVP ...
By nVector
-
Intermountain Primary Children’s Hospital First in Nation to Successfully Implant New Brain Shunt Accessory for Patients with Hydrocephalus
Surgeons at Intermountain Primary Children’s Hospital are the first in the nation to successfully implant a new brain shunt accessory for young patients with hydrocephalus, a neurological condition that causes a buildup of cerebrospinal fluid in the deep cavities of the brain that often causes frequent hospitalizations. This extra fluid puts pressure on the brain and can cause brain ...
-
Anuncia Medical, Inc., receives FDA clearance for the ReFlow System Mini for the treatment of patients with hydrocephalus
Anuncia Medical, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting. Anuncia Medical announced FDA clearance of ReFlow® System Mini for the treatment of cerebrospinal fluid (CSF) disorders. The FDA 510(k) clearance allows ...
-
First-in-Human Use of ReFlow for Treatment of Hydrocephalus
Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful first-in-human implantation of its Alivio ReFlow™ Ventricular System for treatment of hydrocephalus at Boston Children’s Hospital. This announcement comes on the heels of receiving the EU CE Mark and US FDA Clearance of Alivio ...
-
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the ...
-
Anuncia ReFlow Tech Honored With Fast Company 2021 World Changing Ideas Awards
Anuncia Inc., an emerging leader in cerebrospinal fluid (CSF) management, received an Honorable Mention in the Health category of Fast Company’s 2021 World Changing Ideas Awards for its ReFlow™ medical device platform. Those honored were announced today by Fast Company and include businesses actively engaged and deeply committed to pursuing innovation aimed at solving health and ...
-
FONAR Set to Join Russell 3000 and 2000 Indexes
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning, reported today that upon the opening of U.S. markets on June 29, 2020, FONAR will, as part of the annual reconstitution of the Russell Indexes, be joining the broad-market Russell 3000 Index and the Russell 2000 Index. The Russell 3000 Index is a market-capitalization-weighted equity index that tracks the performance of the 3,000 ...
-
Lead Acts to Trigger Schizophrenia
Study in Mice Points to a Synergistic Relationship Between Lead Exposure and Schizophrenia Gene Mice engineered with a human gene for schizophrenia and exposed to lead during early life exhibited behaviors and structural changes in their brains consistent with schizophrenia. Scientists at Columbia University’s Mailman School of Public Health and the Johns Hopkins University School of ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
-
LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this product is expected ...
By RevBio Inc.
-
FONAR Celebrates the 50th Anniversary of the Origination of the MRI
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, celebrated a special anniversary on September 17, 2019: It was 50 years ago that Raymond V. Damadian, M.D., founder and chairman of FONAR Corporation, first thought about developing a device using magnetic resonance to scan the human body to detect cancer. On September 17, 1969, Dr. Damadian sent a letter to Dr. George Mirick ...
-
Microbot Medical to Present the Self-Cleaning Shunt at the 16th Asian Australasian Congress of Neurological Surgeons
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel. Dr Gustavo Rajz, Head of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you